July 2, 2020 -- Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.
The company will develop a stable and safe adjuvant delivery platform against a variety of infectious diseases, including COVID-19. Through the Small Business Innovation Research grant, Inimmune will develop a proprietary synthetic vaccine adjuvant -- components that stimulate and direct the immune system to enhance immunity to a vaccine. The two-year project will be led by Inimmune's Shannon Miller, PhD, and David Burkhart, PhD.
In June, Inimmune announced that they would be collaborating with the University of Montana's Center for Translational Medicine and Rocky Mountain Laboratories for the development of a nasal spray COVID-19 vaccine.